Table 2.

Study objectives

Primary objective	To assess the treatment effect of L-BLP25 plus BSC, as compared to BSC alone, on overall survival time
Secondary objectives	Time to symptom progression (based on LCSS questionnaire)
	Time to progression
	Progression-free survival time
	Time to treatment failure
	Safety
Other objectives	Quality-of-life (EQ-5D/LCSS)
	Healthcare resource utilization and work status
	Biomarkers/pharmacogenetics

BSC: best supportive care; EQ-5D: EuroQol Group 5-Dimension questionnaire; LCSS: Lung Cancer Symptom Scale.